These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome. Seibel I; Cordini D; Rehak M; Hager A; Riechardt AI; Böker A; Heufelder J; Weber A; Gollrad J; Besserer A; Joussen AM Am J Ophthalmol; 2015 Oct; 160(4):628-36. PubMed ID: 26133249 [TBL] [Abstract][Full Text] [Related]
27. Trabeculectomy in patients with uveal melanoma after proton beam therapy. Riechardt AI; Cordini D; Rehak M; Hager A; Seibel I; Böker A; Gundlach E; Heufelder J; Joussen AM Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1379-85. PubMed ID: 26960442 [TBL] [Abstract][Full Text] [Related]
28. Proton Therapy for 166 Patients with Iris Melanoma: Side Effects and Oncologic Outcomes. Gollrad J; Böker A; Vitzthum S; Besserer A; Heufelder J; Gauger U; Böhmer D; Budach V; Zeitz O; Joussen AM Ophthalmol Retina; 2023 Mar; 7(3):266-274. PubMed ID: 36087876 [TBL] [Abstract][Full Text] [Related]
29. Mortality after diagnosis of small melanocytic lesions of the choroid. Lane AM; Egan KM; Kim IK; Gragoudas ES Arch Ophthalmol; 2010 Aug; 128(8):996-1000. PubMed ID: 20696999 [TBL] [Abstract][Full Text] [Related]
30. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837 [TBL] [Abstract][Full Text] [Related]
34. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter. Sabazade S; Herrspiegel C; Gill V; Stålhammar G BMC Cancer; 2021 Nov; 21(1):1270. PubMed ID: 34819035 [TBL] [Abstract][Full Text] [Related]
35. Proton Beam Irradiation: A Safe Procedure in Postequatorial Extraocular Extension From Uveal Melanoma. Seibel I; Riechardt AI; Erb-Eigner K; Böker A; Cordini D; Heufelder J; Joussen AM Am J Ophthalmol; 2018 Jul; 191():49-53. PubMed ID: 29655645 [TBL] [Abstract][Full Text] [Related]
36. [Diffuse malignant melanoma of the uvea. A clinico-histopathologic study of 39 patients]. Braun UC; Rummelt VC; Naumann GO Klin Monbl Augenheilkd; 1998 Dec; 213(6):331-40. PubMed ID: 10048010 [TBL] [Abstract][Full Text] [Related]
37. Proton beam therapy and iris neovascularisation in uveal melanoma. Boyd SR; Gittos A; Richter M; Hungerford JL; Errington RD; Cree IA Eye (Lond); 2006 Jul; 20(7):832-6. PubMed ID: 16167079 [TBL] [Abstract][Full Text] [Related]
38. [Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates]. Desjardins L; Lumbroso L; Levy C; Mazal A; Delacroix S; Rosenwald JC; Dendale R; Plancher C; Asselain B J Fr Ophtalmol; 2003 Mar; 26(3):269-76. PubMed ID: 12746603 [TBL] [Abstract][Full Text] [Related]
39. [Clinical analysis of tumors of the iris and ciliary body]. Liu GQ; Wu ZY; Feng GG; Yang HS; Yan JH; Zheng HL Zhonghua Yan Ke Za Zhi; 2003 Feb; 39(2):77-80. PubMed ID: 12783684 [TBL] [Abstract][Full Text] [Related]